

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 December 2020 (17.12.2020)



(10) International Publication Number
WO 2020/252475 A1

(51) International Patent Classification:

A61K 31/436 (2006.01) A61P 31/04 (2006.01)

A61K 31/65 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2020/037787

(22) International Filing Date:

15 June 2020 (15.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/861,855 14 June 2019 (14.06.2019) US

16/504,723 08 July 2019 (08.07.2019) US

16/565,242 09 September 2019 (09.09.2019) US

(72) Inventor; and

(71) Applicant: **A TIBA, Joshua O.** [US/US]; c/o SoCal IP Law
Group LLP, 310 N. Westlake Blvd., Suite 120, Westlake
Village, California 91362 (US).

(74) Agent: **TAMSUT, Brian S.** et al.; SoCal IP Law Group
LLP, 310 N. Westlake Blvd., Suite 120, Westlake Village,
California 91362 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TRIPLE PHARMACEUTICAL COMPOSITION FOR PROTEINACEOUS INFECTION




FIG. 1

(57) Abstract: There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrP^{Sc} formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.



WO 2020/252475 A1